News for GILEAD SCIENCES (GILDD.BA)

Gilead Sciences (GILD) stock slips as the company agrees to pay $202M to settle allegations that its HIV drug promotion program violated U.S. law. Read more here.

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In.

[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gilead Sci

Summary Bristol-Myers Squibb Co (BMY) has announced its support for the Robert A. Winn Clinical Investigator Pathway Program (Winn CIPP), which launched its fou

Key Insights: Gilead Sciences' (GILD) new HIV treatment, Yeztugo, is endorsed by WHO. Analyst consensus suggests a generally positive outlook for Gilead

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. (”œGilead” or the ”œCom

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 PURPOSE trial data at IAS 2025 showing

Gilead Sciences (GILD) has unveiled promising Phase 3 trial results for lenacapavir, marketed as Yeztugo, highlighting its efficacy and tolerance across diverse

Recent analysis from Leerink has led to an increased price target for Gilead Sciences (GILD), now set at $114, up from the previous $105. The firm maintains an

PR NewswireNEW YORK, July 12, 2025 NEW YORK, July 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences

President Donald Trump said in a letter Thursday that he will raise taxes on many imported goods from Canada to 35%, deepening the rift between the longtime North American allies.

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to

Arcus Biosciences, a strategic partner with Gilead Sciences, gains FDA orphan drug designation for its promising pancreatic cancer treatment. Wall Street an

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapie

Robin Washington, chief operating and financial officer at Salesforce, talks agentic AI and offers career advice.

Strengths: Innovative DEL-AI platform and robust clinical pipeline with potential market exclusivity.Weaknesses: Early-stage clinical development and high risk

In the most recent trading session, Gilead Sciences (GILD) closed at $113.24, indicating a +1.96% shift from the previous trading day.

Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and deepening responses in patients with r/r chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia (WM)

Gilead Sciences (GILD) partners with The Global Fund to enhance access to HIV preventive medication in over 120 countries. Analyst predictions show an a